Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease

ALZHEIMER'S disease is the most common dementing illness and may be the fourth leading cause of death in the United States. It severely affects about 1.4 million Americans, and this number is predicted to increase fivefold in the next half century. 1 2 3 4 The current direct and indirect annual cost of Alzheimer's disease in the United States is estimated to be $24 billion to $48 billion. 4 , 5 The disease has no known cause or effective treatment, although a wide variety of therapeutic approaches have been considered. 6 One medication used for Alzheimer's disease is Hydergine (Sandoz brand of ergoloid mesylates), a preparation containing 0.333 . . .